Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease

Journal of Diabetes Investigation

Volumn 10, Issue 4, 2019, Pages 1004-1011

  Inoue, Mitsuko ^a   Hayashi, Akinori ^a   Taguchi, Tomomi ^a   Arai, Riina ^a   Sasaki, Sayaka ^a   Takano, Koji ^a   Inoue, Yusuke ^a   Shichiri, Masayoshi ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatic fat fraction; Non alcoholic fatty liver disease; Sodium glucose cotransporter 2 inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CANAGLIFLOZIN; CHOLINESTERASE; COLLAGEN TYPE 4; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; HYALURONIC ACID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOELECTRICAL IMPEDANCE ANALYSIS; BODY COMPOSITION; BODY MASS; BODY WATER CONTENT; CHOLINESTERASE BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FAT MASS; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATIC FAT CONTENT; HEPATOBILIARY PARAMETERS; HUMAN; IMPEDANCE; LEAN BODY WEIGHT; MALE; MUSCLE MASS; NAUSEA; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PILOT STUDY; PLATELET COUNT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SIDE EFFECT; URINE VOLUME; ADIPOSE TISSUE; CLINICAL TRIAL; DRUG EFFECT; FOLLOW UP; LIVER; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS;

ADIPOSE TISSUE; ADULT; AGED; BODY COMPOSITION; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85059533640     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12980     Document Type: Article

References (36)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202–1219.
2. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–1419.
3. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263–2273.
4. Hazlehurst JM, Woods C, Marjot T, et al. Non-alcoholic fatty liver disease and diabetes. Metabolism 2016; 65: 1096–1108.
5. Lattuada G, Ragogna F, Perseghin G. Why does NAFLD predict type 2 diabetes? Curr Diab Rep 2011; 11: 167–172.
6. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124–131.
7. Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013; 5: 1544–1560.
8. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614–2618.
9. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449–1457.
10. Reeder SB, Robson PM, Yu H, et al. Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging 2009; 29: 1332–1339.
11. Hope TA, Ohliger MA, Qayyum A. MR imaging of diffuse liver disease: from technique to diagnosis. Radiol Clin North Am 2014; 52: 709–724.
12. Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 2016; 150: 626–637.
13. Guinan EM, Connolly EM, Kennedy MJ, et al. The presentation of metabolic dysfunction and the relationship with energy output in breast cancer survivors: a cross-sectional study. Nutr J 2013; 12: 99.
14. Giessing J, Eichmann B, Steele J, et al. A comparison of low volume ‘high-intensity-training’ and high volume traditional resistance training methods on muscular performance, body composition, and subjective assessments of training. Biol Sport 2016; 33: 241–249.
15. Ellegard L, Bertz F, Winkvist A, et al. Body composition in overweight and obese women postpartum: bioimpedance methods validated by dual energy X-ray absorptiometry and doubly labeled water. Eur J Clin Nutr 2016; 70: 1181–1188.
16. Leahy S, O'Neill C, Sohun R, et al. A comparison of dual energy X-ray absorptiometry and bioelectrical impedance analysis to measure total and segmental body composition in healthy young adults. Eur J Appl Physiol 2012; 112: 589–595.
17. Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55: 885–904.
18. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2014; 104: 297–322.
19. Hayashi A, Takano K, Kawai S, et al. SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies. Endocr J 2016; 63: 187–191.
20. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
21. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in Type 2 diabetes. N Engl J Med 2016; 375: 323–334.
22. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med 2017; 377: 644–657.
23. Tahara A, Kurosaki E, Yokono M, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol 2014; 66: 975–987.
24. Hayashizaki-Someya Y, Kurosaki E, Takasu T, et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol 2015; 754: 19–24.
25. Ito D, Shimizu S, Inoue K, et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with Type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care 2017; 40: 1364–1372.
26. Leiter LA, Forst T, Polidori D, et al. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 2016; 42: 25–32.
27. Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with Type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care 2018; 41: 1801–1808.
28. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317–1325.
29. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104–1112.
30. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846–854.
31. Sato F, Tamura Y, Watada H, et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 2007; 92: 3326–3329.
32. Jojima T, Tomotsune T, Iijima T, et al. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 2016; 8: 45.
33. Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38: 1730–1735.
34. Ohki T, Isogawa A, Toda N, et al. Effectiveness of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors. Clin Drug Investig 2016; 36: 313–319.
35. Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014; 727: 66–74.
36. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020–1031.